
Ipsen has reported positive topline results from its phase 3 BEOND clinical programme evaluating Dysport (abobotulinumtoxinA) for the prevention of …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

